Aclaris Therapeutics (ACRS) Stock Forecast, Price & News

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aclaris Therapeutics in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ACRS shares.
View ACRS analyst ratings or view top-rated stocks.

7 Wall Street research analysts have issued 12-month target prices for Aclaris Therapeutics' shares. Their ACRS share price forecasts range from $20.00 to $43.00. On average, they anticipate the company's stock price to reach $28.83 in the next twelve months. This suggests a possible upside of 360.6% from the stock's current price.
View analysts price targets for ACRS or view top-rated stocks among Wall Street analysts.

Aclaris Therapeutics' stock was trading at $15.75 at the beginning of 2023. Since then, ACRS shares have decreased by 60.3% and is now trading at $6.26.
View the best growth stocks for 2023 here.

Aclaris Therapeutics saw a increase in short interest in September. As of September 15th, there was short interest totaling 6,520,000 shares, an increase of 14.4% from the August 31st total of 5,700,000 shares. Based on an average daily trading volume, of 715,100 shares, the days-to-cover ratio is presently 9.1 days.
View Aclaris Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our ACRS earnings forecast.

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) released its quarterly earnings data on Monday, August, 7th. The biotechnology company reported ($0.42) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.03. The biotechnology company had revenue of $1.90 million for the quarter, compared to analysts' expectations of $1.90 million. Aclaris Therapeutics had a negative trailing twelve-month return on equity of 54.43% and a negative net margin of 337.90%. The business's revenue was up 26.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.31) EPS.

ETFs with the largest weight of Aclaris Therapeutics (NASDAQ:ACRS) stock in their portfolio include Invesco Nasdaq Future Gen 200 ETF (QQQS), SPDR S&P Pharmaceuticals ETF (XPH) and Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).iShares U.S. Pharmaceuticals ETF (IHE).

1 employees have rated Aclaris Therapeutics Chief Executive Officer Neal Walker on Glassdoor.com. Neal Walker has an approval rating of 100% among the company's employees. This puts Neal Walker in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Aclaris Therapeutics investors own include TherapeuticsMD (TXMD), Inovio Pharmaceuticals (INO), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), Trevena (TRVN), AVEO Pharmaceuticals (AVEO), Corbus Pharmaceuticals (CRBP), OPKO Health (OPK), Abeona Therapeutics (ABEO) and Aldeyra Therapeutics (ALDX).

Aclaris Therapeutics trades on the NASDAQ under the ticker symbol "ACRS."

Shares of ACRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ACRS stock can currently be purchased for approximately $6.26.

Aclaris Therapeutics (NASDAQ:ACRS) has a market capitalization of $443.15 million and generates $29.75 million in revenue each year. The biotechnology company earns $-86,910,000.00 in net income (profit) each year or ($1.55) on an earnings per share basis.

Aclaris Therapeutics' mailing address is 640 LEE ROAD SUITE 200, WAYNE PA, 19087. The official website for the company is www.aclaristx.com. The biotechnology company can be reached via phone at (484) 324-7933, via email at investors@aclaristx.com, or via fax at 484-320-2344.